BIOEMTECH technology makes possible what is considered impossible
As always, we are glad to see that BIOEMTECH’s technology makes possible what is considered impossible! Our collaborator at Radiomedix, Inc. are working on novel 212Pb based radiopharmaceuticals for TAT of LDLR overexpressing solid tumors. We are happy that gamma-eye assisted the team to optimize the radiolabeling process and establish the preclinical imaging protocols.
